Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz (EFV) in Women Co-infected With Human Immunodeficiency Virus (HIV) and Tuberculosis (TB)

NCT02412436 is registered in ClinicalTrials.gov with Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections as lead sponsor.

NCT NCT02412436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02412436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz (EFV) in Women Co-infected With Human Immunodeficiency Virus (HIV) and Tuberculosis (TB)
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase
Phase 2
Overall status
Completed
Start date
November 3, 2015
Completion date
June 15, 2017
Enrollment
62 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1 infection, tuberculosis